Presently, from the clinical perspective, the most suitable way to move forward in the management of RA patients is to improve TNF-α pharmacogenomics, considering in the next studies bias such as ethnicity, different criteria to define clinical responder or different kinds of biological agents used that could influence the clinical results and the scientific value of investigations. Here, TNF is linked to rheumatoid arthritis.